Drug Update · Cardiology

FDA Approves Wegovy for CV Risk in Adults with Obesity: MACE 6.5% vs 8%

August 10, 2026

MACE event rate (Wegovy)

6.5% (Wegovy)

MACE event rate (Placebo)

8% (placebo)

Trial size

Randomly assigned over 17,600 participants

Approved maintenance dose (injection)

2.4 mg once weekly (usual recommended maintenance dosage)

Clinical Perspective

Cardiologists, primary care physicians, endocrinologists, and clinicians treating adults with obesity and established cardiovascular disease should recognize that Wegovy (semaglutide) now has an FDA‑approved indication to reduce the risk of major adverse cardiovascular events in this population, based on a large randomized trial reported by the FDA ^[2]^[1]. The source‑confirmed trial data support use of Wegovy for risk reduction of CV death, non‑fatal myocardial infarction, or non‑fatal stroke in adults with established cardiovascular disease and obesity or overweight ^[2]. How clinicians integrate Wegovy into individual patient management will depend on labeled contraindications, tolerability, comorbid conditions, and concurrent therapies, especially agents that increase hypoglycemia risk ^[1].

Dr. Arjun Sharma · Cardiology

The U.S. Food and Drug Administration approved Wegovy (semaglutide) to reduce the risk of major adverse cardiovascular events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. The approval follows a multi-national, placebo-controlled trial in which major adverse cardiovascular events occurred in 6.5% of participants on Wegovy versus 8% on placebo ^[2]^[1].

Clinical Context

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist; semaglutide reduces blood glucose by stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner and is protracted by albumin binding and protection from DPP-4 degradation ^[3]^[1]. Novo Nordisk markets Wegovy as an injectable formulation with labeled indications that include cardiovascular risk reduction in adults with established cardiovascular disease who have obesity or overweight, weight-reduction indications, and other approved uses described in the prescribing information ^[1]. The FDA approval for cardiovascular risk reduction was supported by a large randomized cardiovascular outcomes trial described by the agency ^[2]. Prescribing and monitoring considerations stated in product labeling include contraindications for patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), and multiple listed warnings and precautions in the full prescribing information ^[1].

Key Findings

The pivotal, multi-national, multi-center, placebo-controlled double‑blind trial randomly assigned over 17,600 participants to Wegovy or placebo and assessed major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) ^[2].
In that trial, major adverse cardiovascular events occurred in 6.5% of participants who received Wegovy compared to 8% of participants who received placebo ^[2].
The FDA concluded that Wegovy significantly reduced the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, leading to the new indication for cardiovascular risk reduction ^[2]^[1].

Safety & Tolerability

Boxed warning: Risk of thyroid C‑cell tumors; Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with MEN 2 ^[1].
Acute pancreatitis has been observed; discontinue Wegovy if pancreatitis is suspected ^[1].
Acute gallbladder disease, including cholelithiasis and cholecystitis, has occurred in clinical trials ^[1].
Hypoglycemia: Concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia ^[1].
Acute kidney injury due to volume depletion has been reported; monitor renal function in patients reporting events that could lead to volume depletion ^[1].
Diabetic retinopathy complications have been reported in trials with semaglutide; monitor patients with a history of diabetic retinopathy ^[1].
Heart rate increase: labeling advises monitoring heart rate at regular intervals ^[1].
Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported postmarketing ^[1].
Most common adverse reactions (incidence ≥5% in adults or pediatric patients aged ≥12 years) include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis ^[1].

Study Design

The cardiovascular indication was supported by a multi‑national, multi‑center, placebo‑controlled double‑blind cardiovascular outcomes trial that randomly assigned over 17,600 participants to Wegovy or placebo; the primary endpoint was major adverse cardiovascular events (cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke) ^[2]. The FDA announcement of approval summarized that trial evidence and the resulting reduction in event rates (6.5% Wegovy vs 8% placebo) as the basis for the cardiovascular indication ^[2]. Details on randomization schema, follow‑up duration, and other design elements are described in the prescribing information and FDA materials ^[1]^[2].

FAQ

Q1 What is Wegovy approved for?

Wegovy (semaglutide) injection is approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke) in adults with established cardiovascular disease and either obesity or overweight, when used in addition to a reduced‑calorie diet and increased physical activity. Wegovy is also indicated for chronic weight management and additional labeled indications described in the prescribing information.

Q2 How does semaglutide (Wegovy) work?

Semaglutide is a glucagon‑like peptide‑1 (GLP‑1) receptor agonist that binds and activates the GLP‑1 receptor. It lowers blood glucose by stimulating insulin secretion and lowering glucagon secretion in a glucose‑dependent manner. Semaglutide’s prolonged duration derives from albumin binding and protection from metabolic degradation, contributing to its once‑weekly dosing regimen in the injectable formulation.

Q3 What is the dose of Wegovy for adults on the cardiovascular indication?

The usual recommended maintenance dosage of Wegovy injection in adults is 2.4 mg once weekly for weight reduction and cardiovascular risk reduction per the prescribing information; initiation and escalation schedules are specified in labeling to mitigate gastrointestinal adverse reactions. Dosing for specific indications and patient groups is detailed in the full prescribing information. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the side effects of Wegovy?

Labeling lists a boxed warning for the risk of thyroid C‑cell tumors and contraindication in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Observed and reported adverse events include acute pancreatitis, acute gallbladder disease, hypoglycemia when used with insulin or insulin secretagogues, acute kidney injury due to volume depletion, diabetic retinopathy complications, heart rate increases, hypersensitivity reactions including anaphylaxis and angioedema, and common gastrointestinal and systemic reactions such as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue. The full prescribing information contains additional details on adverse reactions and monitoring.

Clinicians should consult current prescribing information for complete dosing guidance.

FDA Approves Wegovy for CV Risk in Adults with Obesity: MACE 6.5% vs 8%

Direct Clinical Takeaway & Evidence Summary

FDA Approves Wegovy for CV Risk in Adults with Obesity: MACE 6.5% vs 8%

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Cardiology in your inbox.

Related Clinical Updates

FDA Approves Etripamil for PSVT: 64% 30‑min Conversion in RAPID

AZALEA–TIMI 71: Abelacimab Reduced Bleeding Risk (HR 0.38) vs Rivaroxaban in AF

enlicitide Cuts LDL-C 56% and 59% in Phase 3 CORALreef Trials

Verified HCP Portal